Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report issued on Saturday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 3.4 %

Shares of Brooklyn ImmunoTherapeutics stock opened at $0.43 on Friday. Brooklyn ImmunoTherapeutics has a 12-month low of $0.17 and a 12-month high of $10.10. The company has a market cap of $25.00 million, a price-to-earnings ratio of -0.19 and a beta of 4.61. The company’s 50-day moving average price is $0.94 and its 200-day moving average price is $1.51.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.